HALEON PLC 20.2% potential upside indicated by Barclays

HALEON PLC with ticker (LON:HLN) now has a potential upside of 20.2% according to Barclays.



Barclays set a target price of 391 GBX for the company, which when compared to the HALEON PLC share price of 325 GBX at opening today (09/11/2023) indicates a potential upside of 20.2%. Trading has ranged between 268 (52 week low) and 358 (52 week high) with an average of 17,481,231 shares exchanging hands daily. The market capitalisation at the time of writing is £30,349,420,314.

Haleon plc is a consumer healthcare company. The Company’s product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.